FDA approves ‘cooling cap’ to reduce hair loss during chemotherapy A cap that cools the scalp to reduce hair loss (alopecia) in women undergoing chemotherapy for breast cancer has been cleared for marketing by the US Food and Drug Administration.…
FDA approves treatment for inherited bleeding disorder Recombinant von Willebrand factor, a treatment for an inherited bleeding disorder, has been approved by the US Food and Drug Administration.…
Second clinical trial death puts the future of obesity drug in doubt The US Food and Drug Administration has given the pharmaceutical company Zafgen a verbal notice that its investigational new drug application for beloranib has been put on complete clinical hold after the death of a patient during a phase III clinical trial.…
FDA approves new multiple myeloma drug elotuzumab A new immune-stimulating treatment for multiple myeloma has been approved by the US Food and Drug Administration.…
FDA approves necitumumab for non-small cell lung cancer Necitumumab (Portrazza) has been approved by the US drugs safety watchdog as a new combination therapy for patients with advanced squamous non-small cell lung cancer who have not received other treatment for their advanced disease.…
Study supports cardiovascular safety of testosterone Despite FDA warnings, no link found between testosterone therapy and cardiovascular risks.…
FDA approves first oral proteasome inhibitor for multiple myeloma A new combination therapy for patients with multiple myeloma whose previous treatment has failed has been approved by the US Food and Drug Administration.…
FDA approves nasal spray for opioid overdoses The US Food and Drug Administration has approved the first ever nasal spray for the emergency treatment of opioid overdoses manifested by respiratory and/or central nervous system depression.…
Devising ways to improve medicines adherence There are many reasons why patients do not take their medicines as prescribed. Discovering the specific cause of non-adherence is the best way to improve it.…
Clinical trial disclosures for new drugs are below legal and ethical standards, find researchers Clinical trial disclosures for drugs approved by the US Food and Drug Administration fail to meet both the legal and ethical standards expected, according to research published in BMJ Open on 16 November 2015. …
